Stay updated with breaking news from Zymeworks Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease...
Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of
Operator: Ladies and gentlemen, thank you for standing by. This is conference operator. Welcome to Zymeworks Third Quarter 2022 Results Conference Call and Webcast.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks' zanidatamab in key markets, including the U.S., Europe and Japan, pursuant to the license and ...
Stifel raised argenx SE (NASDAQ:ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. ...